BAppSc (Medical Technology), MScTSC, MAICD
Chair of the Regulatory & Quality Committee
With over 35 years in the pharmaceutical and bioscience industries, Lusia Guthrie is an experienced CEO, technology developer and medtech entrepreneur, with strong leadership skills and international industry networks. She started her career as a Medical Laboratory Scientist before joining the Manufacturing Division of pharmaceutical company FH Faulding & Co (now Mayne Pharma). Lusia then went on to co-found medical technology innovation company LBT Innovations Limited (ASX: LBT) where she was Chief Executive Officer and Managing Director until 2016.
Lusia has a proven track record in bringing innovative products to global markets, embracing the entire process from company formation, capital raising and concept development to product launch and sales. She has an ongoing interest in the development and commercialisation of innovative healthcare products that embrace automation, robotics, machine learning and artificial intelligence.
Lusia is a generous contributor to the Australian life sciences sector through various engagements including: Chair of BioMelbourne Network; Chair of the Medical Device Partnering Program in Victoria; Non-Executive Director of 4Dx Limited; and Chair of the Australian Lung Health Initiative. She is a member of the Innovation Taskforce, an initiative of the Victorian Government Minister for Jobs, Innovation and Trade.
She also serves on several advisory boards: Medicines Manufacturing Innovation Centre (MMIC) at Monash University; Australian Institute for Machine Learning (AIML) at the University of Adelaide; and Australian Regenerative Medicine Institute (ARMI).